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OBJECTIVES The study was done to evaluate reliability of echocardiographic left ventricular (LV) mass.
BACKGROUND Echocardiographic estimation of LV mass is affected by several sources of variability.
METHODS We assessed intrapatient reliability of LV mass measurements in 183 hypertensive patients
(68% men, 65 6 9 years) enrolled in the Prospective Randomized Enalapril Study Evaluating
Regression of Ventricular Enlargement (PRESERVE) trial after a screening echocardiogram
(ECHO) showed LV hypertrophy. A second ECHO was repeated at randomization (45 6
25 days later). Two-dimensional (2D)-guided M-mode or 2D linear measurements of LV
cavity and wall dimensions were verified by one experienced reader.
RESULTS Mean LV mass was similar at first and second ECHO (243 6 53 vs. 241 6 54 g) and showed
high reliability as estimated by intraclass correlation coefficient (RHO) 5 0.93. Within-
patient 5th, 10th, 90th and 95th percentiles of between-study difference in LV mass were
232 g, 228 g, 125 g and 135 g. Mean LV mass fell less from the first to the second ECHO
than expected from a formula to predict regression to the mean (2 6 19 vs. 17 6 12 g, p ,
0.001). Reliability was also high for LV internal diameter (RHO 5 0.87), septal (RHO 5
0.85) and posterior wall thickness (RHO 5 0.83). Substantial or moderate reliability was
observed for measures of LV systolic function and diastolic filling (RHO from 0.71 to 0.57).
CONCLUSIONS Left ventricular mass had high reliability and little regression to the mean; between-study LV
mass change of 635 g or 617 g had $95% or $80% likelihood of being true change. (J Am
Coll Cardiol 1999;34:1625–32) © 1999 by the American College of Cardiology
Cardiovascular mortality and morbidity increase with in-
creasing values of left ventricular (LV) mass independently
of other cardiovascular risk factors (1–6). High LV mass
also reflects cumulative effects of cardiovascular risk factors
(7,8). Therefore, estimation of LV mass represents an
important task for cardiovascular risk stratification.
See page 1633
Echocardiography is more sensitive for assessing LV
hypertrophy than electrocardiography (9,10). Although the
ability of echocardiography to measure cardiac structure and
function noninvasively is generally accepted, this modality is
affected by several sources of variability (11). Thus, recom-
mendations have been produced to enhance reproducibility
of measurements and to facilitate comparison among labo-
ratories (12–15).
Regression of echocardiographic LV hypertrophy has a
beneficial impact on cardiovascular mobility and mortality
(16). However, the phenomenon of regression to the mean
may cause misleading results in studies of regression of LV
hypertrophy (17,18). This phenomenon typically occurs
when studies select subjects because a variable (i.e., LV
mass) exceeds a specified partition. Because of regression to
the mean, reevaluation of the selected population may reveal
a lower mean value of the variable in question than on first
evaluation simply because of random fluctuation of mea-
surements (17,19). This phenomenon may confound inter-
pretation of studies on regression of LV hypertrophy in
which patient recruitment is based on LV mass exceeding a
partition value. However, the higher the reliability of
measurements the less regression to the mean occurs (18).
We assessed the reliability of measurements of LV mass
and indices of LV systolic function and diastolic filling in
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the Prospective Randomized Enalapril Study Evaluating
Regression of Ventricular Enlargement (PRESERVE) (20),
a multicenter trial to compare the efficacy of enalapril with
long-acting nifedipine to reduce LV mass and improve LV
filling in hypertensive patients with LV hypertrophy.
METHODS
Patients. The study population consisted of hypertensive
women and men aged $50 years enrolled in the PRE-
SERVE study. To enter the study, patients had to have
seated blood pressure .140 and/or 90 mm Hg if on
medication or .150 and/or 90 mm Hg if unmedicated
during four weeks before the echocardiographic screening.
Patients with LV hypertrophy [LV mass index .116 g/m2
in men and in women ,60 years of age and .104 g/m2 in
older women (1,21)], on a screening echocardiogram that
showed ejection fraction .40% and no severe valvular
disease and/or cardiomyopathy received at least one week of
placebo before the baseline echocardiographic evaluation at
randomization. All patients gave written informed consent
to the study.
Full LV and Doppler measurements were obtained on
screening studies for approximately the first 60% of patients
to evaluate the reliability of echocardiographic parameters
between screening and baseline evaluation. Studies were
initially blindly read by skilled readers (VP, JNB, GdeS or
MP): 183 of 212 subjects with full screening echocardio-
graphic measurements had them verified, and in a majority
of patients at least one measurement was corrected by a
single, highly experienced reader (RBD).
Echocardiography. Sonographers received extensive train-
ing in the PRESERVE protocol including both written
material and didactic and hands-on training at the Reading
Center in New York. The standardized echocardiographic
protocol required recording of $10 cycles of two-
dimensional (2D) parasternal long- and short-axis LV views
and $10 cycles of M-mode with optimal cursor beam
orientation in each view (20 –23). If the 2D-guided
M-mode beam could not be optimally oriented, 2D-long
axis views were used to obtain linear measurements of LV
cavity and walls according to American Society of Echocar-
diography recommendations (23). The LV mass was calcu-
lated by an anatomically validated formula (24). Left ven-
tricular endocardial fractional shortening (FS), midwall
shortening (MWS) and circumferential end-systolic stress
(ESS) measure of afterload were derived (25). To assess LV
systolic performance adjusted for afterload, stress-corrected
fractional shortening (c-FS) and stress-corrected midwall
shortening (c-MWS) were derived (25). Pulse-wave Dopp-
ler flow pattern at mitral anulus was traced electronically to
measure peak velocities of early and late diastolic LV filling.
Statistical analysis. Data are reported as mean 6 SD.
Intraobserver and interobserver components of variability of
measurements were not assessed.
Paired-sample t tests were used to evaluate differences
between measurements on first and second echocardiogram.
The reliability of echocardiographic measurements was
investigated using two methods. The intraclass correlation
coefficient (RHO), an estimator of variability between





where MSt was calculated as MSt 5 (MSb 2 MSw)/K0, and
where MSb is the between-subject mean square of variance,
a measure of between-subject variability; MSw is the within-
subject mean square of variance; and K0 is the number of
repeated measurements (two in this study). Analysis of
variance for repeated measures was used to estimate MSb
and MSw. If the ratio MSw/MSb decreases, RHO increases.
The closer RHO is to 1 the higher is the proportion of the
variance of measurements free from random errors. Conse-
quently, reliability of measurements increases based on the
assumption that MSw is an unbiased estimator of within-
subject variability due to random error of measurements of
a variable, whereas MSt is an unbiased estimator of the
error-free between-subject variability (18). The 95% confi-
dence interval (CI) of RHO was estimated using a two-way
random effect model for absolute agreement.
The second method to assess reliability was the Bland-
Altman (26) within-patient interevaluation interval of
agreement of LV mass estimation (as absolute value and as
percent change from screening evaluation). The 5th to 95th
percentile confidence interval (90% CI) was used to derive
thresholds of LV mass change that minimize two-tailed
alpha-errors at 5%; 90th, 85th, 80th, 75th, 67th, 33rd, 25th,
20th, 15th, and 10th percentiles of between-study difference
in LV mass were also generated, to identify the b- and
a-error associated with different thresholds of LV mass
change.
Abbreviations and Acronyms
BMI 5 body mass index
BP 5 blood pressure
BSA 5 body surface area
c-FS 5 stress-corrected fractional shortening
c-MWS 5 stress-corrected midwall shortening
ESS 5 end-systolic stress
FS 5 fractional shortening
LV 5 left ventricular
MSb 5 between-subject mean square of variance
MSw 5 within-subject mean square of variance
MWS 5 midwall shortening
PRESERVE 5 Prospective Randomized Enalapril Study
Evaluating Regression of Ventricular
Enlargement
RHO 5 intraclass correlation coefficient
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Standard deviations (SD) of between-study difference in
LV mass and LV mass index were used to estimate sample
size needed to detect between-group differences in regres-
sion of LV mass with statistical powers at 90% and 80%,
and a-errors of 5% and 1%.
Previously reported (19) formulae were used to estimate
change in absolute and indexed LV mass. Follow-up LV
mass was predicted from screening values by the following
formulae:
1. Rg(%) 5 3910/LVMg 2 23, where Rg(%) is the percent
reduction expected for absolute LV mass at the second
evaluation and LVMg is initial LV mass in grams (g).
2. Rg/m2(%) 5 2700/LVMg/m2 2 30, where Rg/m2(%) is the
percent reduction expected for LV mass/body surface
area expected at the second evaluation and LVMg/m2 is
the initial LV mass index.
Paired-sample t tests were performed to compare predicted
LV mass to actual LV mass on the second echocardiogram,
in the entire population and in quintiles of the distribution
of initial LV mass values.
Relations between interstudy change of LV mass and
demographic, clinical and echocardiographic parameters
were assessed by Pearson correlations and multiple linear
regression analyses. Two-tailed p , 0.05 was considered
significant.
RESULTS
Subjects’ characteristics. One hundred eighty-three pa-
tients (68% men, mean age 65 6 9 years, from 28 centers)
had paired echocardiograms 45 6 25 days apart at screening
and at randomization into the PRESERVE trial. Body mass
index (BMI) and body surface area (BSA) were similar at
two evaluations (r 5 0.97, r 5 0.99, respectively). Systolic
blood pressure (BP) rose between screening at baseline visit
(163 6 17 vs. 169 6 20 mm Hg, p 5 0.001, r 5 0.44),
while mean diastolic BP did not rise (96 6 11 vs. 98 6
11 mm Hg, p . 0.1; r 5 0.57). Mean heart rate at both
visits was 64 6 11 beats/min (p . 0.1; r 5 0.60).
Reliability and regression to the mean. The between-
study difference in LV mass was 21.7 6 19.8 g for absolute
values, 21.1 6 11.2 g/m2 for LV mass/BSA and 20.4 6
5.2 g/m2.7 for LV mass/Height2.7 (Table 1). The relation
between LV mass measured at screening and baseline is
illustrated in Figure 1. The RHO was 0.90 or higher for
absolute LV mass and indexed values. Mean LV internal
diameter and wall thickness did not differ between evalua-
tions (p . 0.1). Of the primary measures used to derive LV
mass, LV diastolic diameter showed the highest RHO.
The within-patient, interevaluation 90% CI of agreement
ranged from 214% (5th percentile, 232 g) to 115% (95th
percentile, 135 g) for absolute LV mass (Fig. 2), from
214% (217.8 g/m2) to 114% (119.3 g/m2) for LV mass/
BSA and 214% (28.7 g/m2.7) to 115% (19.1 g/m2.7) for
LV mass/Height2.7 (Table 2).
Predicted decreases in LV mass from screening to base-
line due to regression to the mean were 26.8% for absolute
LV mass (217 g) and 29.7% for LV mass/BSA (213 g/m2).
Predicted LV mass was significantly lower than observed
values at baseline evaluation (226 6 41 g vs. 241 6 54 g,
p , 0.0005); predicted LV mass/BSA (125 6 19 g/m2) was
Figure 1. Relation between screening values of LV mass (hori-
zontal axis) and LV mass measured at subsequent baseline
echocardiogram (vertical axis).








LV mass (g) 243 6 53 241 6 54 0.93 (0.91–0.95)
LV mass/height2.7 (g/m2.7) 63 6 15 63 6 15 0.94 (0.92–0.95)
LV mass/BSA (g/m2) 135 6 25 134 6 25 0.90 (0.87–0.93)
IVS (cm) 1.2 6 0.2 1.2 6 0.2 0.85 (0.80–0.88)
LVID (cm) 5.5 6 0.5 5.5 6 0.5 0.87 (0.82–0.90)
PWT (cm) 1.1 6 0.1 1.1 6 0.1 0.83 (0.77–0.86)
BSA 5 body surface area; IVS 5 interventricular septal thickness; LVID 5 LV internal dimension; PWT 5 posterior wall
thickness. Results are mean 6 SD. Paired-differences are nonsignificant.
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also lower than observed baseline LV mass index (134 6
26 g/m2, p , 0.005).
Measured LV mass at screening and baseline was com-
pared in each quintile of screening LV mass (Fig. 3). No
differences were observed between screening and baseline
mean LV mass in the 1st to 4th quintile (1st: 186 vs. 187 g;
2nd: 215 vs. 214 g; 3rd: 234 vs. 234 g; 4th: 256 vs. 256 g,
all p . 0.1), whereas in the 5th quintile LV mass at baseline
was lower than at screening (318 g vs. 326 g, p , 0.05).
Similar results were obtained using LV mass/BSA (data not
shown). We compared LV mass measured at baseline to LV
mass predicted by formulae to assess regression to the mean
in each quintile of screening LV mass. At the lowest
quintile, the difference between observed and predicted LV
mass did not reach statistical significance (187 vs. 182 g;
p 5 0.06), but in all higher quintiles mean observed LV
mass at baseline significantly exceeded predicted LV mass
(2nd: 214 vs. 204 g; 3rd: 234 vs. 219 g; 4th: 256 vs. 236 g;
5th 318 vs. 291 g, all p , 0.001) (Fig. 3). Similar results
were obtained for LV mass/BSA (data not shown).
Figure 2. Bland-Altman plot of interevaluation agreement of LV mass estimation. Between-study mean LV mass (horizontal axis) is
plotted against between-study difference of LV mass in single patients (vertical axis).
Table 2. Likelihood of True Changes in LV Mass for Different Thresholds
of Intraindividual Variability
LV Mass Change Likelihood of
g (%) (g/m2) (g/m2.7) True Increase (%) True Decrease (%)
$135 (14.9) $19.3 $9.1 95 —
$125 (10.8) $15.0 $7.1 90 —
$119 (9.3) $11.2 $5.1 87.5 —
$116 (6.6) $8.0 $3.9 85 —
$113 (5.6) $6.6 $3.2 80 —
$17 (3.3) $4.1 $2.0 75 —
$15 (1.6) $2.1 $1.1 67 —
#210 (24.2) #26.4 #22.7 — 67
#214 (25.7) #27.9 #23.6 — 75
#217 (26.2) #29.3 #24.1 — 80
#221 (27.7) #212.3 #25.4 — 85
#226 (28.7) #214.8 #26.1 — 87.5
#228 (210.8) #216.0 #27.0 — 90
#232 (214.2) #217.8 #28.7 — 95
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Confidence intervals of LV mass changes: Likelihood of
true changes. As a consequence of the observed between-
evaluation variability, in a single patient there is a 5% chance
that an LV mass variability greater than 135 g does not
represent a true increase (Table 2). This likelihood rises to
10% for an increase of 25 g, 15% for an increase of 16 g,
20% for an increase of 13 g, 25% for an increase of 7 g and
33% for an increase of 5 g. In the other direction, for a
between-evaluation LV mass variability of 210 g there
is a 33% chance that LV mass is not truly decreased, 25%
for a decrease of 14 g, 20% for a decrease of 17 g, 15% for
a decrease of 21 g, 10% for a decrease of 28 g and 5% for a
decrease of 32 g.
Impact of variability of LV mass estimation on detection
of LV hypertrophy regression. Table 3 shows the sample
size needed per group to detect between-group difference in
LV mass change with statistical power at 80% and 90%, and
alpha-errors of 5% and 1%, using SDs of between-study
differences in LV mass of 19.8 g, 11.2 g/m2 and 5.3 g/m2.7.
A between-group difference of 10 g/m2 would be detected
with 28 or 40 patients per group with 90% statistical power
at 5% and 1% a-errors. Sample sizes needed per group for
other levels of between-group difference in LV mass and LV
mass indices are reported in Table 3. Using a between-
echocardiogram difference SD of 20 g/m2 over a long term
($1 year) (27) instead of 11.2 g/m2 in the present analysis,
86 or 121 patients per arm are required to detect a
between-arm difference of 10 g/m2 with 90% power and
a-errors of 5% and 1%.
Correlates of the variability of LV mass. Differences in LV
mass between evaluations (Table 4) were positively related to
differences in LV internal diameter (r 5 0.38), interventricular
septal thickness (r 5 0.43) and posterior wall thickness (r 5
0.59) (all p , 0.0005). Gender, age and between-study change
in weight did not significantly affect LV mass. Differences in
systolic or diastolic blood pressure did not correlate signifi-
cantly with differences in LV mass, possibly owing to the
narrow range of their changes. Additionally, no significant
associations were found between variability in LV mass and
screening levels of body weight, blood pressure, LV internal
diameter or Doppler-stroke volume.
Prevalence of LV hypertrophy at the second study.
Predefined criteria for LV hypertrophy were met by 159
patients (87%) on the second evaluation. Comparing pa-
tients in whom LV hypertrophy was or was not confirmed,
the latter group had lower LV mass at screening (120 vs.
137 g/m2, p , 0.001) and lower systolic (157 vs.
165 mm Hg, p , 0.05) but not diastolic blood pressure (97
vs. 96 mm Hg, p . 0.1). The two subgroups were
comparable in proportion of women (24% vs. 33%) and age
(66 6 8 vs. 65 6 8 years). Body weight did not change
between evaluations in either subgroup (p . 0.1).
Reliability of measurements of LV systolic function.
Mean FS and MWS did not differ between evaluations (p .
0.1) (Table 5). The RHO was 0.68 for MWS, and 0.65 for
FS. Circumferential ESS rose minimally between echocar-
diograms (183 to 188 kdyne p cm22, p 5 0.06, RHO 5
0.60). Changes in ESS were negatively related to changes in
FS (r 5 20.56) and MWS (r 5 20.28). The RHO for
stress-corrected MWS was higher than for stress-corrected
FS (0.71 vs. 0.56).
Figure 3. Mean values (vertical axis) of observed LV mass at
screening (striped bars) and at baseline (filled bars) and of LV
mass predicted by a formula to calculate regression to the mean
(open bars) in hypertensive patients classified by quintiles of LV
mass on screening echocardiogram (horizontal axis). *p , 0.05.
**p , 0.001.
Table 3. Sample Size (n) per Group Needed for Statistical
Power of 90% or 80% to Detect Changes in LV Mass at
Alpha-Errors of 5% and 1%
Group Differences














10 g 84 63 119 94
15 g 38 29 54 43
20 g 22 17 31 25
25 g 15 11 21 17
LV mass/BSA
6 g/m2 75 56 106 84
8 g/m2 43 32 61 48
10 g/m2 28 21 40 31
12 g/m2 20 15 28 23
LV mass/Height2.7
2 g/m2.7 149 112 211 166
3 g/m2.7 67 50 95 75
4 g/m2.7 38 29 54 43
5 g/m2.7 25 19 36 28
Computation assumes a standard deviation of 19.8 g for change in LV mass,
11.2 g/m2 for LV mass/BSA, and 5.2 g/m2.7 for LV mass/Height2.7.
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Reliability of left ventricular diastolic filling. Left ven-
tricular filling was measured at mitral anulus on both
examinations in 111 patients. Peak velocity of early LV
diastolic filling “E” wave (54 6 17 vs. 53 6 21 cm/s, p .
0.1, between-study difference SD 5 17.5 cm/s, RHO 5
0.58) and peak velocity of late LV diastolic filling “A” wave
(73 6 20 vs. 71 6 20 cm/s, p . 0.1, between-study
difference SD 5 18.6 cm/s, RHO 5 0.57) showed moder-
ate reliability. Interstudy change “E” peak velocity was
related to change of LV internal diameter (r 5 0.25, p ,
0.05), but not of body weight, heart rate, systolic or diastolic
blood pressure (all p . 0.1). Change of peak “A” velocity
was not related to any considered variable.
DISCUSSION
Reliability of estimation of LV mass. In the present study,
reliability of echocardiographic measurements of LV mass,
internal dimension and wall thickness was relatively high
(28). To our knowledge, this is the first study of this
question in a large cohort of hypertensive patients with LV
hypertrophy. In accord with the high reliability of LV mass,
mean LV mass measured at baseline was significantly higher
than LV mass predicted from screening values by a formula
to estimate regression to the mean (19). Slight regression to
the mean was detected only in the highest quintile of
screening LV mass values (Fig. 3). However, the regression
to the mean was less than expected, because baseline LV
mass significantly exceeded values predicted by the equa-
tions of Herpin and Demange (19).
Findings of this study demonstrate that homogeneity of
echocardiographic readings can be achieved in a multicenter
study on regression of LV mass in patients with LV
hypertrophy. Centralized reading with a single and highly
experienced final arbiter of readings, use of standardized
echocardiographic protocol and a “hands-on” training pro-
gram for sonographers (20) may have contributed to re-
duced variability and regression to the mean of LV mass
estimation. Substitution of linear measurements of LV wall
thickness and internal dimension from the 2D-long axis
view whenever the M-mode beam was not ideally oriented
may also have contributed to the relatively low variability
and regression to the mean observed in this study. Because
of the greater mean age and BMI of participants in
PRESERVE, the majority of measurements were made
from 2D views. Potential limitations of the M-mode to
obtain reproducible LV mass measurements have been
addressed (29–31). Although 2D echocardiography can also
be affected by difficulties in obtaining correct long-axis views
or in delineating endocardial and epicardial borders, our
findings suggest that a protocol emphasizing obtaining
long-axis views that maximize LV chamber size achieves
high reliability of LV mass whichever echocardiographic
display (M-mode or long-axis 2D) best demonstrates cor-
rect interface definition and measurement orientation (32).
Additionally, the fact that screening and baseline studies
from multiple centers were read interspersed with each
other as they arrived at the Reading Center attenuated
potential bias due to recall of the first evaluation at the
reading of the second.
Our study shows that an intraindividual increase or
decrease of calculated LV mass greater than 18 g/m2 (or
34 g) is needed to be at least 95% certain that there has been
a true change in that direction. Because of the study design,
this variability includes intrapatient biologic variability, as
well as intrareader and intrasonographer variabilities. It is
worthy of consideration that for other clinically relevant
variables exhibiting measurement variability, like arterial
blood pressure, changes that are 80% or even 75% likely to
represent true decrease, corresponding to LV mass changes
of 17 g or 14 g, are commonly used to guide clinical
Table 4. Relation Between Change of LV Mass and Dimensions and Hemodynamic Parameters
DSBP DWeight DLVID DIVS DPWT DSV Age Gender
DLVM r 5 0.03 r 5 20.05 r 5 0.38 r 5 0.43 r 5 0.59 r 5 0.09 r 5 0.05 r 5 20.09
(p . 0.1) (p . 0.1) (p , 0.0005) (p , 0.0005) (p , 0.0005) (p . 0.1) (p . 0.1) (p . 0.1)
D 5 difference between first and second study; SBP 5 systolic blood pressure; SV 5 Doppler-derived stroke volume. Other abbreviations as in Table 1.








FS (%) 34 6 5 34 6 5 0.65 (0.55 6 0.75)
MWS (%) 16 6 2 16 6 02 0.68 (0.60–0.75)
ESS (kdynepcm22) 183 6 42 188 6 44 0.60 (0.49–0.70)
c-FS (%) 137 6 17 138 6 17 0.56 (0.44–0.66)
c-MWS (%) 103 6 14 102 6 14 0.71 (0.62–0.78)
Results are mean 6 SD. All paired-differences are nonsignificant.
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decisions. The relevance for risk stratification of change in
LV mass in hypertensive patients has been recently reported
(16) and implications of using LV mass change as a
surrogate end point have been discussed (33). Based on the
present findings, groups of 41 patients per treatment arm
need to complete the period of randomized treatment to
provide statistical power of 90% at an alpha-error level of
1% to detect a between-group difference of at least 10 g/m2
in LV mass. Assuming 20 g/m2 as SD of between-study
difference in LV mass over a larger between-study interval,
86 patients per treatment arm should provide 90% power at
an alpha-error of 5% to detect a between-group difference of
10 g/m2 in LV mass. Thus, the PRESERVE trial (in which
over 200 patients completed the year of treatment) has
better-than-anticipated power to detect the hypothesized
difference between treatment arms in LV hypertrophy
regression (20).
Reliability of assessment of LV systolic function and
diastolic filling. Mean MWS and FS did not differ be-
tween studies, and the reliability of measurements of systolic
function fell in the “substantial” range (28). The LV systolic
performance is a dynamic process dependent on a beat-to-
beat balance among preload, afterload and myocardial con-
tractility. When afterload was taken into account, c-MWS
had a higher RHO than did unadjusted values (0.71 vs.
0.68), whereas RHO for c-FS was lower than for FS itself
(0.56 vs. 0.65).
Doppler peak velocity of “E” and “A” waves, parameters
of LV diastolic filling, showed “moderate” reliability. Heart
rate, systolic BP and circumferential ESS, variables related
to LV filling, showed moderate between-study correlations
(r 5 0.44 to r 5 0.60).
Study limitations. Evaluation of interobserver variability
of LV dimension and LV mass measurements was not a
goal of our study. Our readings were verified by a single
experienced reader, which may have reduced the variability
of estimation of LV mass by eliminating potential interob-
server variability among readers in a single center and, even
more, between readers in different centers.
Part of the variability of serial estimations of LV dimen-
sions and mass detected in our study is potentially due to
intraindividual biological variability over the mean interval
of six weeks between echocardiograms. A short between-
study interval (e.g., on the same day or within a few days)
would better relate observed measurement variability to
intra- or interreader variability rather than biological vari-
ability. The inability to show significant associations of
between-study echocardiographic measurement variability
with changes in body weight, blood pressure or heart rate
may reflect imprecision in clinical as well as echocardio-
graphic measurements. Of note, the small increase in
systolic blood pressure between screening and baseline
echocardiograms may have attenuated the reduction of LV
mass that might otherwise have occurred due to the regres-
sion to the mean. Finally, this study does not address the
important issue of long-term measurement “drift” even
within a single reading center. However, we have previously
reported that change in LV mass in normotensive subjects
over three to six years was as low as 6 g, after accounting for
change in BMI, systolic blood pressure and 24-h urinary
sodium excretion (34).
Conclusions. The reliability of 2D echocardiographic
measurements of primary LV structures and LV mass
between screening and baseline phases of the PRESERVE
trial was fairly high, showing little regression to the mean.
Short-term between-study variability in LV mass of 634 g
or 618 g in single patients have, respectively, $90% or
$80% likelihood to be true changes in the identified
direction. Thus, echocardiographic evaluation of LV
mass using a standardized protocol and a Central Read-
ing Center is able to detect even small changes of LV
mass in modest-sized populations. The clinical relevance
of LV mass change at different thresholds of confidence
for likelihood of true change in single patients needs
further study.
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